[1]陶祥,张文斐,冀保卫,等.抑制SSRP1对胶质瘤细胞增殖、化疗敏感性的影响[J].中国临床神经外科杂志,2022,27(09):760-764.[doi:10.13798/j.issn.1009-153X.2022.09.013]
　TAO Xiang,ZHANG Wen-fei,JI Bao-wei,et al.Effect of inhibition of SSRP1 on glioma cells proliferation and chemosensitivity to temozolomide[J].,2022,27(09):760-764.[doi:10.13798/j.issn.1009-153X.2022.09.013]
点击复制

抑制SSRP1对胶质瘤细胞增殖、化疗敏感性的影响()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年09期
页码:
760-764
栏目:
实验研究
出版日期:
2022-09-30

文章信息/Info

Title:
Effect of inhibition of SSRP1 on glioma cells proliferation and chemosensitivity to temozolomide
文章编号:
1009-153X（2022）09-0760-05
作者:
陶祥; 张文斐; 冀保卫; 张戈; 陈治标
430060 武汉，武汉大学人民医院神经外科（陶祥、张文斐、冀保卫、张戈、陈治标）
Author(s):
TAO Xiang;  ZHANG Wen-fei;  JI Bao-wei;  ZHANG Ge;  CHEN Zhi-biao
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
关键词:
胶质瘤; 结构特异性识别蛋1（SSRP1）; CBL0137; 细胞增殖; U251细胞; U87细胞; 化疗敏感性; 预后
Keywords:
Glioma;  Structure specific recognition protein 1 (SSRP1);  CBL0137;  Cell proliferation;  Chemotherapy;  Prognosis
分类号:
R739.41
DOI:
10.13798/j.issn.1009-153X.2022.09.013
文献标志码:
A
摘要:
目的 探讨结构特异性识别蛋白1（SSRP1）与胶质瘤预后的相关性，以及抑制SSRP1对胶质瘤细胞增殖及化疗敏感性的影响。方法 应用生信分析方法，检索中国胶质瘤数据库CGGA数据集，分析SSRP1表达与胶质瘤预后相关性。体外培养胶质瘤U251、U87细胞，应用CBL0137抑制SSRP1，应用替莫唑胺（TMZ）检测化疗敏感性。应用CCK8法检测细胞增殖，利用免疫印迹法检测MAPK信号通路（p-38、ERK及JNK）表达。结果 生信分析结果显示，胶质瘤SSRP1呈高表达，随胶质瘤级别增加，SSRP1表达明星上调（P<0.05）；SSRP1高表达胶质瘤总生存期明显缩短（P<0.05）。抑制SSRP1，明显抑制体外培养U251、U87细胞增殖（P<0.05），增加U251、U87细胞对TMZ化疗敏感性（P<0.05），对U251、U87细胞p-38、ERK及JNK蛋白表达水平无明显影响，但明显降低U251、U87细胞p-38、ERK及JNK蛋白磷酸化水平（P<0.05）。结论 胶质瘤SSRP1呈高表达，与病人不良预后有关；抑制SSRP1，明显抑制胶质瘤细胞增殖，并增加其对TMZ的化疗敏感性，其机制可能与抑制MAPK信号通路有关。
Abstract:
Objective To investigate the correlation between expression of structure specific recognition protein 1 (SSRP1) and prognoses of glioma patients, and the effect of inhibiting SSRP1 on glioma cells proliferation and chemotherapy sensitivity to temozolomide (TMZ). Methods The CGGA dataset of China Glioma Database was serched and the correlation between SSRP1 expression and prognosis of glioma patients was analyzed using bioinformatics analysis method. The U251 and U87 cells were cultured in vitro, CBL0137 was used to inhibit SSRP1, and TMZ was used to detect the sensitivity of chemotherapy. Cell proliferation was detected by CCK8 assay, and the expression of MAPK signaling pathway (p-38, ERK and JNK) was detected by Western blotting. Results The results of bioinformatics analysis showed that the expression of SSRP1 was high in glioma; the expression of SSRP1 was up-regulated with the increase of glioma grade (P<0.05); the overall survival time of glioma patients with high SSRP1 expression was significantly shorter than those with low SSRP1 expression (P<0.05). Inhibition of SSRP1 significantly inhibited the proliferation of U251 and U87 cells in vitro (P<0.05), increased the sensitivity of U251 and U87 cells to TMZ chemotherapy (P<0.05), and had no significant effect on the protein expression levels of p-38, ERK and JNK in U251 and U87 cells (P>0.05). However, the phosphorylation levels of p-38, ERK and JNK protein in U251 and U87 cells were significantly decreased (P<0.05). Conclusions The high expression of SSRP1 in glioma is associated with poor prognosis. Inhibition of SSRP1 can significantly inhibit the proliferation of glioma cells and increase their sensitivity to TMZ chemotherapy, which may be related to the inhibition of MAPK signaling pathway.

参考文献/References:

[1] Liu Y, Zhou K, Zhang N, et al. FACT caught in the act of manipulating the nucleosome [J]. Nature, 2020, 577(7790): 426-431.
[2] Marciano G, Da V S, Tria G, et al. Structure-specific recognition protein-1 (SSRP1) is an elongated homodimer that binds histones [J]. J Biol Chem, 2018, 293(26): 10071-10083.
[3] Wu W, He K, Guo Q, et al. SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p [J]. J Cell Mol Med, 2019, 23(5): 3118-3129.
[4] Wang Q, Jia S, Jiao Y, et al. SSRP1 influences colorectal cancer cell growth and apoptosis via the AKT pathway [J]. Int J Med Sci, 2019, 16(12): 1573-1582.
[5] Song H, Zeng J, Lele S, et al. APE1 and SSRP1 is over-expressed in muscle invasive bladder cancer and associated with poor survival [J]. Heliyon, 2021,7(4): e6756.
[6] Ding Q, He K, Luo T, et al. SSRP1 contributes to the malignancy of hepatocellular carcinoma and is negatively regulated by miR-497 [J]. Mol Ther, 2016, 24(5): 903-914.
[7] Shen J, Chen M, Lee D, et al. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression [J]. Gut, 2020, 69(2): 329-342.
[8] Min J, Jin D, Zhang F, et al. DLG1-AS1 is activated by MYC and drives the proliferation and migration of hepato-cellular carcinoma cells through miR-497-5p/SSRP1 axis [J]. Cancer Cell Int, 2021, 21(1): 16.
[9] Jin G, Zhao R, Zhang J, et al. SSRP1 affects the growth and apoptosis of gastric cancer cells through AKT pathway [J]. J Med Biochem, 2022, 41(1): 100-107.
[10] Yu Y, Gao Y, Yu Y. SSRP1 worsens malignant melanoma progression by activating MAPKs pathway [J]. Ann Clin Lab Sci, 2021, 51(6): 783-789.
[11] Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity [J]. Int J Mol Sci, 2020, 21(3): 1102.
[12] Perreault S, Larouche V, Tabori U, et al. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01 [J]. BMC Cancer, 2019, 19(1): 1250.
[13] Dermawan JK, Hitomi M, Silver DJ, et al. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models [J]. Cancer Res, 2016, 76(8): 2432-2442.
[14] De S, Lindner DJ, Coleman CJ, et al. The FACT inhibitor CBL0137 synergizes with cisplatin in small-cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells [J]. Cancer Res, 2018, 78(9): 2396-2406.
[15] Jin MZ, Xia BR, Xu Y, et al. Curaxin CBL0137 exerts anti-cancer activity via diverse mechanisms [J]. Front Oncol, 2018, 8: 598.
[16] Han N, Yang L, Zhang X, et al. LncRNA MATN1-AS1 prevents glioblastoma cell from proliferation and invasion via RELA regulation and MAPK signaling pathway [J]. Ann Transl Med, 2019, 7(23): 784.
[17] He J, Huang Z, He M, et al. Circular RNA MAPK4 (circ-MAPK4) inhibits cell apoptosis via MAPK signaling path-way by sponging miR-125a-3p in gliomas [J]. Mol Cancer, 2020, 19(1): 17.
[18] Chen X, Hao A, Li X, et al. Activation of JNK and p38 MAPK mediated by ZDHHC17 drives glioblastoma multi-forme development and malignant progression [J]. Thera-nostics, 2020, 10(3): 998-1015.
[19] Chen L, Gong X, Huang M. YY1-activated long noncoding RNA SNHG5 promotes glioblastoma cell proliferation through p38/MAPK signaling pathway [J]. Cancer Biother Radiopharm, 2019, 34(9): 589-596.
[20] Cao Y, Zhang L, Wang Y. Antitumor activity of cedrelone in temozolomide-resistant human glioma cells is accompanied by mitochondrial mediated apoptosis, inhibition of angio-genesis, cell cycle disruption and modulation of ERK/MAPK signalling pathway [J]. J BUON, 2019, 24(3): 1204-1209.

相似文献/References:

[1]常英男　王　策　赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
　CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(09):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛　克　陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许　耿　路俊锋　杨　忠　施建斌　吴秋月　王　烨　庄冬晓　吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
　XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(09):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰　陈银生　赛　克　张湘衡　柯　超　杨群英　牟永告　许海雄　陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
　LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(09):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波　杨宇焦　张　逵　范润金　张　渊　杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
　YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(09):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚　成于思　王　辉　汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
　HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(09):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林　雨　张　恺　李　帅　杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明　徐成仕　王泽芬　曹长军　李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
　DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(09):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生　田道锋　张申起　陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
　PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(09):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯　驰　郭双毅　程龙海　罗　杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
　FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(09):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]

备注/Memo

备注/Memo:
（2022-05-30收稿，2022-07-21修回）
通讯作者：陈治标，E-mail：chenzbrenmin @163.com
更新日期/Last Update: 2022-10-31